T.P.2 01 Longer-term (>3 months) IVIG treatment to optimize clinical benefit and cellular protection usually requires an individualized adjustable schedule – not fixed regimentation
W.K. EngelVolume:
16
Year:
2006
Language:
english
DOI:
10.1016/j.nmd.2006.05.193
File:
PDF, 59 KB
english, 2006